MeDiCU

MeDiCU is a South Korean biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapeutics. The company utilizes its proprietary MeDi-Degrader platform to design bifunctional small molecules that selectively eliminate disease-causing proteins by hijacking the body's natural protein disposal system. MeDiCU's primary research focus is on oncology, specifically targeting "undruggable" proteins such as STAT3 to address unmet needs in cancer treatment. By combining advanced medicinal chemistry with structural biology, the company aims to overcome the limitations of traditional occupancy-based inhibitors. MeDiCU is currently advancing a pipeline of preclinical candidates while establishing strategic partnerships to expand its technological capabilities.